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Abstract
The pathogenesis of neuromyelitis optica (NMO) involves binding of IgG autoantibodies (NMO-IgG) to aquaporin-4 (AQP4)
on astrocytes in the central nervous system (CNS). We studied the in vivo processing in mice of a recombinant monoclonal
human NMO-IgG that binds strongly to mouse AQP4. Following intravenous administration, serum [NMO-IgG] decreased
with t1/2 ,18 hours in wildtype mice and ,41 hours in AQP4 knockout mice. NMO-IgG was localized to AQP4-expressing
cell membranes in kidney (collecting duct), skeletal muscle, trachea (epithelial cells) and stomach (parietal cells). NMO-IgG
was seen on astrocytes in the area postrema in brain, but not elsewhere in brain, spinal cord, optic nerve or retina.
Intravenously administered NMO-IgG was also seen in brain following mechanical disruption of the blood-brain barrier.
Selective cellular localization was not found for control (non-NMO) IgG, or for NMO-IgG in AQP4 knockout mice. NMO-IgG
injected directly into brain parenchyma diffused over an area of ,5m m
2 over 24 hours and targeted astrocyte foot-
processes. Our data establish NMO-IgG pharmacokinetics and tissue distribution in mice. The rapid access of serum NMO-
IgG to AQP4 in peripheral organs but not the CNS indicates that restricted antibody access cannot account for the absence
of NMO pathology in peripheral organs.
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Introduction
Neuromyelitis optica (NMO) is an autoimmune inflammatory
disease of the central nervous system (CNS) associated with
demyelinating lesions mainly in optic nerve and spinal cord,
leading to blindness and paralysis [1,2]. The majority of NMO
patients are seropositive for autoantibodies (NMO-IgG) against
extracellular epitope(s) on aquaporin-4 (AQP4) [3,4,5], a plasma
membrane water channel expressed in astrocytes throughout the
CNS [6,7]. AQP4 is also expressed in cell plasma membranes in
various peripheral tissues, including kidney collecting duct, skeletal
muscle, gastric parietal cells, tracheal epithelial cells, airway
epithelium and exocrine gland epithelium [6,8]. Mice deficient in
AQP4 do not manifest significant baseline abnormalities in the
CNS, but show, under appropriate stresses, impairment in brain
and spinal cord water balance, neuroexcitation and glial scar
formation [9]. AQP4-deficient mice do not manifest significant
peripheral abnormalities, such as skeletal muscle dysfunction [10]
or reduced gastric acid secretion [11], except for a very mild
impairment in maximal urinary concentrating ability [12].
Indirect evidence suggesting that serum NMO-IgG is patho-
genic includes the high specificity of NMO-IgG seropositivity for
NMO [1], correlations between serum NMO-IgG titers and
disease activity [13,14], loss of AQP4 in NMO lesions [15], and
the clinical benefit of NMO-IgG depletion by plasma exchange
[16]. There is considerable interest in the development of animal
models of NMO for elucidation of the mechanisms of NMO
disease pathogenesis and for testing of candidate therapies. In rats
with pre-existing neuroinflammation, as produced in models of
experimental autoimmune encephalomyelitis, peripheral NMO-
IgG or recombinant AQP4 antibody administration produces
neuroinflammatory lesions [17,18,19]. In naı ¨ve mice, intracerebral
administration of NMO-IgG with human complement produces
lesions with NMO-like characteristics including inflammation, loss
of AQP4 and GFAP immunoreactivity, perivascular deposition of
activated complement, and myelin loss [20]. NMO-IgG binding to
AQP4 in astrocytes is thought to initiate a cascade of inflammatory
events, including antibody-dependent complement and cell-
mediated astrocyte damage, leukocyte recruitment, cytokine
release and demyelination [1,21,22].
Though the rodent data suggest a pathogenic role of NMO-IgG
in NMO, they involve non-physiological maneuvers such as
induction of pre-existing neuroinflammation or direct infusion of
NMO-IgG and complement into brain. Key unresolved issues in
NMO pathogenesis include the preponderance of NMO lesions in
optic nerve and spinal cord over brain and peripheral AQP4-
expressing tissues, and the mechanisms by which NMO-IgG in the
blood enters the CNS to initiate disease.
To test the hypothesis that restricted access of serum NMO-IgG
to AQP4 in peripheral tissues might account for the absence of
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27412NMO pathology in the periphery, and as a first step in generating
mouse models of NMO based on peripheral NMO-IgG
administration, we determined the cellular distribution and
pharmacokinetics of NMO-IgG following peripheral and CNS
administration. For these studies we used a recombinant
monoclonal human NMO-IgG antibody (rAb-53) that was
characterized previously [17,23] and found here to bind strongly
to mouse AQP4. The use of purified monoclonal human NMO-
IgG allowed the sensitive and unambiguous determination of
antibody localization and serum concentration in mice, which is
not possible using human NMO serum or purified IgG in which
NMO-IgG comprises a very small fraction of total IgG.
Results
Human monoclonal NMO-IgG antibody rAb-53 binds to
mouse AQP4
A series of monoclonal recombinant antibodies was previously
generated by single-cell PCR done on individual plasmablasts
from cerebrospinal fluid of NMO patients [17]. We found that
recombinant antibody rAb-53, which strongly binds to human
AQP4 [23], bound well to mouse AQP4 and caused NMO-like
lesions following intracerebral administration (data not shown).
AQP4 is expressed in astrocytes as well as in other tissues as two
major isoforms resulting from alternative transcripts with transla-
tion initiation at Met-1 (M1) and Met-23 (M23) [24,25]. M23-
AQP4 forms orthogonal arrays of particles (OAPs), which are
membrane aggregates that assemble in regular arrays, whereas
M1-AQP4 does not [26]. Previous studies have shown that OAPs
are the preferential target of NMO-IgG [23,27].
Fig. 1A shows staining of CHO cells that were transiently
transfected with the M1 or M23 isoforms of mouse AQP4. NMO-
IgG (rAb-53) bound well to both the M1 and M23 isoforms
(Fig. 1A), as well as to primary cultures of astrocytes from neonatal
mouse brain (Fig. 1B), in which both the M1 and M23 AQP4
isoforms are present and coassemble in heterotetramers that form
OAPs [28]. Staining was not seen in non-transfected CHO cells
(Fig. 1A) or in astrocyte cultures from AQP4 knockout mice
(Fig. 1B). Fluorescence micrographs in Fig. 1C show concentra-
tion-dependent binding of rAb-53 to mouse M23-AQP4. As
quantified by the ratio of red (NMO-IgG) to green (AQP4)
fluorescence (Fig. 1C), antibody binding fitted well to a single-site
binding model, as found previously with human M23-AQP4 [23].
The apparent dissociation constant for rAb-53 binding to mouse
M23-AQP4 was 111639 nM. Fig. 1D shows kinetics of rAb-53
binding to mouse M23-AQP4 after incubation with rAb-53 and
after washout. NMO-IgG binding occurs over tens of minutes and
washout over many hours.
NMO-IgG pharmacokinetics
The pharmacokinetics of NMO-IgG in mice was determined
from the time course of serum concentration following intravenous
administration of 20 mg antibody by tail vein. As a human IgG1
antibody, NMO-IgG concentration in mouse serum was assayed
by ELISA, without interference by the great excess of mouse IgG.
Fig. 2 shows decreasing NMO-IgG concentration over 48 hours
following injection, with t1/2 ,18 hours. To determine whether
binding to AQP4 facilitated NMO-IgG clearance from blood,
parallel studies were done in weight-matched AQP4 knockout
mice. AQP4 deletion significantly slowed the disappearance of
NMO-IgG, with t1/2 ,41 hours (Fig. 2), suggesting that binding of
NMO-IgG to AQP4-expressing tissues such as skeletal muscle in
wild type mice reduces its serum concentration. In addition, a
control human IgG1 antibody that does not target any mouse
antigen had a relatively long t1/2 ,58 hours in wild type mice.
These t1/2 values are in the range of those found for human IgGs
in mice [29].
In vivo targeting of NMO-IgG to AQP4-expressing tissues
The tissue distribution of NMO-IgG was determined at 1 and
24 hours after intravenous administration, in which tissues were
fixed and immunostained for AQP4 using an anti-AQP4 antibody
and for NMO-IgG using an anti-human IgG fluorescent
secondary antibody. NMO-IgG localization was studied in the
major AQP4-expressing peripheral organs, including kidney,
skeletal muscle, trachea and stomach. Studies were done in wild
type and AQP4 knockout mice, as well as using a control (non-
NMO) IgG in place of NMO-IgG. As shown in Fig. 3, AQP4
expression was found in wild type mice on the basolateral
membrane of kidney collecting duct (panel A), the plasmalemma
of fast-twitch fibers in skeletal muscle (panel B), the basolateral
membrane of tracheal surface epithelial cells (panel C) and the
basolateral membrane of gastric parietal epithelial cells (panel D).
Immunostaining was negative in all tissues from AQP4 knockout
mice. NMO-IgG colocalized with AQP4 in each of the tissues
from wild type mice. Interestingly, there was some heterogeneity
in NMO-IgG binding to AQP4-expressing cells (Fig. 3B), which
may be due to variable accessibility of the antibody. NMO-IgG
was not detected in tissues from AQP4 knockout mice, nor was
human IgG detected in wild type mice following injection of
control (non-NMO) IgG. Similar NMO-IgG localization was
found in tissues from 3 mice studied at 24 hours after injection and
2 mice studied at 1 hour after injection (not shown), albeit with
mildly reduced fluorescence.
Immunofluorescence was also done in AQP4-expressing tissues
of the CNS from the same mice. AQP4 expression was seen on
astrocytes in optic nerve, spinal cord and brain as well as on retinal
Muller cells (Fig. 4A). However, except for the few restricted areas
described below, NMO-IgG was not detected in these tissues
following intravenous administration, despite a thorough exami-
nation of different regions of brain and spinal cord. Since NMO
lesions have been reported in the area postrema of a few NMO
patients [30], we labeled circumventricular organs, which lack an
intact blood-brain barrier, by tail vein injection with Evans Blue.
Remarkably, strong NMO-IgG binding to AQP4 was observed in
the area postrema (Fig. 4B) as well as in the arcuate hypothalamic
nucleus (not shown) following intravenous administration. No
binding of a control IgG was detected in these areas (Fig. 4B).
Attempts to enhance delivery of circulating NMO-IgG to
the CNS
We tested maneuvers known to permeabilize the blood-brain
barrier in an attempt to target intravenously administered NMO-
IgG to AQP4 in brain and spinal cord. Pertussis toxin is known to
permeabilize the blood-brain barrier and hence used to potentiate
experimental allergic encephalomyelitis (EAE) in mice [31]. LPS
has also been used to permeabilize the blood-brain barrier [32].
Pertussistoxin and LPStreatments increased the permeability of the
blood-brain barrier to Evans blue by ,2 and 4 fold, respectively
(Fig. 4C). However, no NMO-IgG was detected in brain and spinal
cord following LPS (Fig. 4D) or pertussis toxin (data not shown)
administration. As a positive control, we found serum NMO-IgG in
brain following mechanical damage to the blood-brain barrier
produced by injuring superficial brain with a high-speed drill.
Fig. 4E shows NMO-IgG binding in brain cortex near the site of
mechanical injury (left panel). NMO-IgG colocalized with AQP4 at
the end-feet of astrocytes in a perivascular pattern (Fig. 4E, right
panels). We also investigated if NMO-IgG could access the
NMO Autoantibody Processing in Mice
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may be more permissive [33]. Pregnant mice (embryonic stage E18-
E19)wereinjected with50 mgNMO-IgG(orcontrolIgG)bythetail
vein. After 24 hours, fetal organs were stained for NMO-IgG and
AQP4 (Fig. 4F). At this stage, AQP4 is expressed in kidney and
showed NMO-IgG localization (Fig. 4F), indicating passage of
NMO-IgG between the maternal and fetal circulations. However,
NMO-IgG was not detected in fetal brain or spinal cord, despite
demonstrable AQP4 expression (Fig. 4F).
Diffusion and binding of NMO-IgG in brain following
intracerebral injection
The fate of NMO-IgG in brain tissue was investigated by
fluorescence imaging of brain sections at different times after direct
intra-parenchymal injection for Cy3-labeled NMO-IgG. We
reasoned that NMO-IgG localization would depend on its
diffusion in brain extracellular space and binding to AQP4 on
astrocytes. Low magnification imaging in Fig. 5A shows
progressively increasing areas of Cy3 fluorescence over time.
Figure 1. Binding of a recombinant monoclonal NMO-IgG to mouse AQP4. A. CHO cells expressing mouse M1 or M23 AQP4 were labeled
with an anti-AQP4 C-terminus antibody (green) and recombinant monoclonal NMO antibody rAb-53 (labeled ‘NMO-IgG’, red). B. Binding of NMO-IgG
to primary astrocyte cultures from wild type (+/+) and AQP4 null (-/-) mouse brain. C. (left) Fluorescence micrographs of NMO-IgG (red) binding to
mouse M23-AQP4 as a function of concentration. AQP4 labeled with AQP4 antibody (green). (right) NMO-IgG binding to mouse M23-AQP4 shown as
ratio of red (NMO-IgG) to green (reference AQP4) fluorescence (mean6S.E., n=10). Curve is fit to a single-site binding model. D. Binding kinetics of
NMO-IgG (rAb-53, 50 mg/ml, red) to mouse M23-AQP4 (green). Unbinding measured following 120 min incubation and washout for indicated times
(mean6S.E., n=10). Data are representative of 2 independent sets of experiments.
doi:10.1371/journal.pone.0027412.g001
NMO Autoantibody Processing in Mice
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function of time, showing an area of Cy3 fluorescence of 4.8 mm
2
at 24 hours in wild type mice. The area was 4.1 mm
2 at 3 hours,
suggesting that the NMO-IgG was bound to AQP4 and thus
restricted, as supported by an increased area of Cy3 fluorescence
in mice lacking AQP4 (6.2 mm
2). High magnification confocal
imaging showed localization of injected NMO-IgG to astrocyte
foot processes around vessels, which colocalized with AQP4
expression (Fig. 5B). Selective localization was not seen following
injection of NMO-IgG in brain of AQP4 knockout mice or
injection of control (non-NMO) IgG in brain of wild type mice
(Fig. 5B).
Discussion
In human NMO the concentration of NMO-IgG in serum is
five hundred-fold or greater than that in cerebrospinal fluid [14].
How and when serum NMO-IgG enters the CNS to cause
neuroinflammation and demyelination is unclear, as is why
peripheral, AQP4-expressing organs are not affected in NMO.
Our study addressed several questions: (a) does serum NMO-IgG
access AQP4 in peripheral and central organs?; (b) under what
conditions can serum NMO-IgG enter the CNS?; and (c) once in
the CNS, over what area and at what rate does NMO-IgG diffuse?
To address these questions we administrated a recombinant
human monoclonal antibody in mice, either intravenously or
directly into brain parenchyma, using as key controls an isotype-
matched control human recombinant antibody, and mice lacking
AQP4. In addition to addressing the NMO pathogenesis-relevant
questions, our studies provide the first information on NMO-IgG
pharmacology and tissue distribution for development of NMO
mouse models.
We found that intravenously administered NMO-IgG was
cleared slowly from serum in an AQP4-dependent manner, and
rapidly accessed AQP4 in cell membranes in peripheral organs
where AQP4 is expressed, including kidney, skeletal muscle,
stomach and trachea. The relatively unrestricted access of NMO-
IgG to AQP4 in peripheral tissues is a consequence of IgG
diffusion across the leaky capillary endothelial barrier and binding
to extracellular epitopes on cell surface-expressed AQP4. Selective
AQP4 localization was not seen for control antibody or in AQP4
knockout mice, indicating the specificity of the NMO-IgG for
AQP4. The ready access of NMO-IgG to AQP4-containing cells
in the periphery indicates that restricted access cannot account for
the absence of NMO pathology in non-CNS tissues. Therefore,
other mechanisms to account for the resistance of peripheral
tissues to NMO-IgG damage, such as differences in astrocyte vs.
peripheral cell biology, mandate consideration.
Though intravenously administrated NMO-IgG was readily
visualized in AQP4-expressing cells throughout the periphery,
with one exception it was undetectable throughout CNS tissues
including brain, spinal cord, optic nerve and retina, despite the
sensitivity and specificity of the anti-human fluorescent secondary
antibody. However, strong binding of NMO-IgG to AQP4 in
brain was found in circumventricular organs such as area
postrema, which contain fenestrated endothelial cells that allow
diffusion from blood into brain tissue [34]. Interestingly, NMO-
like lesions have recently been reported in the area postrema in
some NMO patients with nausea and vomiting at clinical
presentation [30]. These restricted lesions are characterized by a
loss of AQP4 expression, inflammation and perivascular comple-
ment deposition. Our finding provides a potential explanation for
the pathogenesis of these lesions. The permissive blood-brain
barrier in the area postrema allows binding of NMO-IgG to
AQP4, resulting in astrocyte pathology and chemosensory
dysfunction. Indeed, it has been shown in cell culture in vitro and
in brain in vivo that NMO-IgG activates complement, leading to
astrocyte cytotoxicity, which accounts for the loss of AQP4, GFAP
and complement deposition in NMO lesions [20,35]. It has also
been demonstrated in vitro that NMO-IgG can damage astrocytes
in a complement-independent manner by recruiting natural killer
cells [17,36]. Primary astrocyte injury and initiation of an
inflammatory cascade are believed to secondarily damage
oligodendrocytes and neurons. However, for the studies here we
did not expect NMO lesions in the area postrema because a
human NMO recombinant antibody was used. It has been shown
that intracerebral injection of purified IgG from serum of NMO
patients causes lesions only when coinjected with human
complement and not with mouse complement [20]. Engineering
chimeric recombinant NMO antibodies, containing a mouse Fc
portion, may be useful in follow-on work attempting to produce
pathological lesions following peripheral antibody administration.
Various maneuvers to transiently permeabilize the blood-brain
barrier, including peripheral pertussis toxin and LPS, did not
result in detectable NMO-IgG deposition in CNS tissues. These
maneuvers probably do not permeabilize the blood-brain barrier
enough to allow robust passage of large macromolecules such as
antibodies, despite increased permeability to Evans Blue. Other
maneuvers causing greater blood-brain barrier permeabilization
and non-specific systemic inflammation may allow more efficient
antibody entry. For example, a recent study reported astrocyte
damage after passive transfer of purified IgG from serum of NMO
patients to rats immunized with complete Freund’s adjuvant (CFA)
Figure 2. Serum pharmacokinetics of NMO-IgG. Serum antibody
concentration (NMO-IgG and control IgG) in wild type (+/+) and AQP4
knockout (-/-) mice quantified by ELISA at 10 min, and 1, 24 and
48 hours after intravenous injection. Data are expressed in mg/mL and
plotted on a log2 scale (mean6S.E., 4 mice per group). *P,0.05
compared with NMO-IgG +/+. #P,0.05 compared with NMO-IgG -/-.
doi:10.1371/journal.pone.0027412.g002
NMO Autoantibody Processing in Mice
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permeabilize the blood-brain barrier and allow entry of NMO-
IgG into the CNS, although perivascular loss of AQP4 and GFAP
was observed with IgG from only one out of three NMO patients
[37]. Localization of intravenously administered NMO-IgG in
brain was seen only after mechanical disruption of the blood-brain
barrier. These data highlight the unresolved issue of how NMO-
IgG enters the CNS to produce pathology especially in spinal cord
and optic nerve. Perhaps small amounts of NMO-IgG, which are
below the detection limit here, enter the CNS spontaneously or
following a systemic inflammatory challenge. Alternatively,
intrathecal plasmablasts producing anti-AQP4 autoantibodies
may initiate CNS lesion formation resulting in initial blood-brain
barrier breakdown through astrocyte destruction and CNS
inflammation [17]. Plasma cells have been reported in both the
CSF and tissue of NMO patients [17,30,38]. Following initial
blood-brain barrier breakdown, continued entry of NMO-IgG
into the CNS might establish a positive-feedback cycle of astrocyte
damage, release and recruitment of inflammatory cells and
mediators, and further breakdown of the blood-brain barrier.
With regard to development of mouse models of NMO based on
peripheral NMO-IgG administration, though serum antibody
concentrations can be maintained, there is little or no CNS
penetration of NMO-IgG in naı ¨ve mice, except for cirumven-
tricular tissues or with various established maneuvers to permea-
bilize the blood-brain barrier.
Administration of NMO-IgG directly into brain by intraparen-
chymal infusion, which bypasses the blood-brain barrier, repro-
ducibly produces NMO-like lesions when coinjected with human
complement [20]. We found here that following single-site
injection into brain parenchyma, NMO-IgG remained relatively
localized in a 4.8 mm
2 region around the injection site.
Photobleaching measurement of FITC-dextran diffusion in brain
suggest that molecules of IgG size are expected to diffuse
throughout brain extracellular space [39]. The substantially
restricted diffusion of NMO-IgG is the consequence of binding
to astrocyte AQP4, as NMO-IgG diffusion was increased in brain
of AQP4 knockout mice.
In conclusion, our studies establish pharmacological data on the
processing of NMO-IgG in mice, including pharmacokinetics and
tissue distribution. These data will facilitate the development of
mouse models of NMO. The rapid and relatively unrestricted
access of intravenously administered NMO-IgG to AQP4-
expressing peripheral but not CNS tissues mandates the need for
further investigation to explain the CNS specificity of NMO
pathology and for development of creative strategies to promote
access of NMO-IgG into the CNS to create animal models.
Materials and Methods
Mice
The generation of AQP4 null mice used in this study was
described previously [12]. All experiments were performed on
weight-matched wild type and AQP4 null mice on a CD1 genetic
background, generally of age 16–18 weeks. Mice were maintained
in air-filtered cages and fed normal mouse chow in the U.C.S.F
Figure 3. NMO-IgG localization to AQP4-expressing peripheral organs following intravenous administration. NMO-IgG or a control
human IgG were injected intravenously in wild type and AQP4 knockout mice. After 24 hours, tissues were fixed and stained for AQP4 (green). NMO-
IgG and control IgG were detected using a secondary anti-human antibody (red). Confocal fluorescence images shown of kidney (A), skeletal muscle
(B), trachea (C) and stomach (D). Arrowheads indicate basolateral membrane of kidney collecting duct (A), skeletal muscle sarcolemma (B), basolateral
membrane of tracheal surface epithelial cells (C), and basolateral membrane of gastric parietal cells (D). Data are representative of 3 mice per group.
doi:10.1371/journal.pone.0027412.g003
NMO Autoantibody Processing in Mice
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U.C.S.F Committee on Animal research.
NMO antibody, DNA constructs, cell culture and
transfection
Purified human monoclonal NMO-IgG rAb-53 was generated as
described [17], with a measles virus-specific rAb (2B4) used as an
isotype-matched control [40]. Fluorescent labeling of NMO-IgG with
Cy3 was done using the Amersham Cy3 Ab Labelling Kit (GE
H e a l t h c a r e ,B u c k i n g h a m s h i r e ,U K ) .D N Ac o n s t r u c t se n c o d i n gf u l l -
length mouse AQP4 (M1 and M23 isoforms) were generated by
PCR-amplification using whole brain cDNA as template. PCR
fragments were ligated into mammalian expression plasmid
pcDNA3.1 and sequenced. Chinese Hamster Ovary (CHO-K1) cells
(ATCC CCL-61) were cultured at 37uCi n5 %C O 2/95% air in F12
Ham’s medium containing 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin. Cells wer eg r o w no ng l a s sc o v e r s l i p sa n d
transfected with plasmids in antibiotic-free medium using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) according to the manufactur-
er’s protocol. Primary astrocyte cultures were generated from cortex
Figure 4. NMO-IgG localization in AQP4-expressing cells in the central nervous system following intravenous administration.
A. Confocal fluorescence images for studies as in Fig. 3, showing AQP4 (green) and NMO-IgG (red) in retina, optic nerve, spinal cord and brain. B.
Binding of NMO-IgG in the area postrema in brain. C. Evans blue quantification in brain of control mice and mice treated with pertussis toxin (PTX) or
LPS (mean6S.E., 4 mice per group). D. Confocal fluorescence images showing AQP4 (green) and NMO-IgG (red) in brain and spinal cord of mice
treated with LPS. E. Intravenously injected NMO-IgG enters brain parenchyma near the site of mechanical injury (dashed line, left panel) and binds to
AQP4 on astrocyte end-feet around blood vessels (right panels). Data are representative of 4 mice. F. Pregnant mice (3 mice) were injected
intravenously with NMO-IgG or control IgG. After 24 hours, embryos were fixed and stained for AQP4 (green) and NMO-IgG or control IgG (anti-
human antibody, red).
doi:10.1371/journal.pone.0027412.g004
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10 days in cultures, cells were treated for two weeks with 0.25 mM
dibutyryl cAMP (Sigma-Aldrich, St. Louis, MO) to induce differen-
tiation. Immunocytochemistry showed that . 95% of cells were
positive for the astrocyte marker, glial fibrillary acidic protein (GFAP).
Immunocytochemistry
AQP4-expressingcellswereincubatedfor20 mininblockingbuffer
(PBS containing 6 mM glucose, 1 mM pyruvate, 1% bovine serum
albumin)andthenfor30 minwithNMO-IgG(20 mg/mL)inblocking
buffer. Cells were then rinsed extensively with PBS, fixed in 4%
paraformaldehydefor15 minandpermeabilizedwith0.1%TritonX-
100. Cells were then blocked again and incubated for 30 min with
0.4 mg/mL polyclonal, C-terminal-specific rabbit anti-AQP4 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA), then rinsed with
PBS. Cells were then incubated for 30 min with 4 mg/mL goat anti-
human IgG-conjugated Alexa Fluor 555 and goat anti-rabbit IgG-
conjugated Alexa Fluor 488 (Invitrogen). Measurements of NMO-
IgG/AQP4 binding affinity and kineti c sw e r ed o n ea sd e s c r i b e d[ 2 3 ] .
Pharmacokinetics
Wild-type or AQP4 null mice (weight-matched, 38–42 g) were
injected by tail vein with 20 mg NMO-IgG or control IgG in
100 mL PBS. After 10 min, and 1, 24 and 48 hours, blood was
collected through the tail vein, left for 30 min at room temperature
to allow clotting of fibrinogen and platelets, and centrifuged for
15 min at 15006g, 4uC. Serum was diluted 100-fold and NMO-
IgG concentration was determined using a human IgG ELISA kit
(GenWay, San Diego, CA). Serum from non-injected mice was
used for background subtraction. Antibody half-life was calculated
by linear regression on log2-transformed serum concentration as a
function of time.
Tissue distribution
Mice were injected with NMO-IgG as above. At 1 and 24 hours
mice were anesthetized using 2,2,2-tribromoethanol (250 mg/kg
intraperitoneally, Sigma-Aldrich) and perfused through the left
cardiac ventricle with 20 mL PBS and then 10 mL of PBS
containing 4% paraformaldehyde (PFA). AQP4-expressing tissues
were removed, post-fixed 2 hours in 4% PFA and dehydrated
overnight in 30% sucrose at 4uC. Tissues were embedded and
frozen in OCT compound (Sakura Finetek, Torrance, CA) for
sectioning and immunostaining. To label circumventricular organs
in brain, 4% Evans Blue solution (200 mL) was injected by tail vein
2 hours before sacrifice. In some experiments pregnant mice (E18-
19) were injected by tail vein with 50 mg NMO-IgG in 100 mL
Figure 5. Binding and diffusion of NMO-IgG in mouse brain. A. Fluorescence micrographs showing distribution pattern of Cy3-labeled NMO-
IgG at indicated times after direct injection into brain parenchyma in wild type (+/+) or AQP4 null mice (-/-). White line, needle track; yellow dashed
line, area of NMO-IgG diffusion. Sections were also stained for AQP4 (green). The graph summarizes areas of Cy3 fluorescence (mm
2, mean6S.E., 3
mice per group). B. Confocal fluorescence images showing colocalization of NMO-IgG (red) with AQP4 (green) in a perivascular pattern (3 h after
injection).
doi:10.1371/journal.pone.0027412.g005
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fetal tissues were processed as described above.
Tissue immunofluorescence
Ten mm-thick frozen sections were blocked for 1 hour in PBS
containing 10% goat serum (blocking buffer) and incubated for
1 hour at room temperature with 0.4 mg/mL rabbit anti-AQP4
antibody (Santa Cruz Biotechnology) diluted in blocking buffer.
Anti-AQP4 antibody was detected using 4 mg/mL goat anti-rabbit
IgG-conjugated Alexa Fluor 488 (Invitrogen). NMO-IgG (or
control IgG) was detected using 4 mg/mL goat anti-human IgG-
conjugated Alexa Fluor 555 (Invitrogen). Sections were then
washed with PBS and mounted in Vectashield medium (Vector
Laboratories, Burlingame, CA). Slides were imaged using a laser
scanning confocal microscope D-Eclipse C1 (Nikon) equipped
with a Nikon 1006, NA 1.49 Apo TIRF objective lens.
Intracerebral injection of NMO-IgG
Mice were anesthetized as described above and mounted on a
stereotactic frame. A midline scalp incision was made and a burr
hole of diameter 1 mm was drilled in the skull 1 mm to the right
and 1 mm posterior to bregma. A 30-gauge needle attached to 50-
mL gas-tight glass syringe (Hamilton) was inserted 3 mm deep to
infuse 3 mg NMO-IgG-Cy3 (or control antibody) in a volume of
10 mL( ,1 mL/min). At specified times after injection (3 mice per
time point), mice were anesthetized and perfused through the left
cardiac ventricle with 5 mL PBS and then 20 mL of PBS
containing 4% PFA. Brains were post-fixed 2 hours in 4% PFA
and processed for paraffin embedding. Five mm-thick sections were
used for immunostaining. Areas of diffusion were quantified from
fluorescence micrographs using Image J.
Blood-brain barrier permeabilization
The blood-brain barrier was transiently permeabilized by
intravenous injection of 250 ng pertussis toxin (from Bordetella
pertussis, Sigma-Aldrich) in 100 mL PBS in the tail vein [31]. After
24 hours, an identical dose of toxin was administered together
with 20 mg NMO-IgG in 100 mL PBS by tail vein injection. The
blood-brain barrier was also permeabilized by intraperitoneal
injection of LPS (E. coli, 055:B5, Sigma-Aldrich) at a dose of 3 mg/
kg diluted in PBS to 0.3 mg/mL [32]. The LPS treatment was
given twice, 48 hours apart, followed 24 hours later with NMO-
IgG by tail vein injection. Control mice were injected with NMO-
IgG in the same manner but received no pertussis toxin and no
LPS (4 mice per group). Twenty-four hours following NMO-IgG
administration, mice were injected intravenously with 4% Evans
blue solution (160 mg/kg in PBS, Sigma-Aldrich) and sacrificed
2 hours later. At that time the left cardiac ventricle was perfused
with 20 mL PBS. Half of the brain was fixed overnight at 4uCi n
4% PFA and processed as described above for immunofluores-
cence. The other half of each tissue was weighed and immersed in
1 mL formamide (Sigma-Aldrich) at 55uC overnight to extract the
Evans blue dye. Extracted dye was quantified by optical
absorbance at 610 nm against Evans blue/formamide standards.
Permeability of the blood-brain barrier to Evans blue was reported
as mg of Evans blue per gram tissue. Spinal cord from these mice
was also collected for immunofluorescence. Mechanical disruption
of the blood-brain barrier in superficial brain cortex was
accomplished by creating a burr hole in the skull using a high-
speed drill as described earlier. NMO-IgG was injected into the
tail vein 15 min before the surgery and mice were sacrificed
24 hours later.
Statistical analysis
All data are presented as mean6S.E. The comparison of two
groups in Fig. 2 and Fig. 4 was performed using unpaired two-
tailed t-test.
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